'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments
Fuente:
FierceBiotech
After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient well-being, particularly for those with rare diseases.